Hikma Pharmaceuticals PLC

So I can welcome everyone to Hikma's interim results Q&A. We have Sayed Derwaza, our CEO, Khaled Nabilsi, our chief financial officer, and Riyad Mishlawi, president of Injectables and our incoming CEO. So welcome, everyone. We hope that you have all had a chance to review the presentation, and we will use this session for Q&A. For people in the room, if you have questions, please take the mic off the table and answer your question using the mic.

Again, good morning, everybody, and welcome to Hikma's results for the first half. As you can see, we think that every division has performed extremely well. The injectables have shown good growth, and Khaled will explain later that there were some extra costs on that division. He will explain in detail what they were. But the growth in sales was good. Launch of products was good. We were able to launch a lot of what we call 505 products. And these are products typically that are new to the market. So they are like in between a generic and a branded. For instance, is usually used in one gram, and that's the originator, and that doesn't come in a stronger form. strength, but we got approved two and three grams, two and three grams. So it's something new for the hospital, and there are many, many products that we got approved. So they're really good products, but they need a little bit of promotion, so they're somewhere between, as I said, the branded and the generic, but we think that they would do extremely well because they really address what the patients need and what the hospitals need. Europe did extremely well. MENA did extremely well. The U.S. is doing fine. It's picking up, and Riyad will explain a little bit more later on. MENA, again, although we had some very, very difficult headwinds with the currency situation in Egypt and Sudan, the unfortunate happenings in Sudan, we still managed to give a very good result with growth

It's almost 17%.